Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Previous issues

Page Path
HOME > BROWSE ARTICLES > Previous issues
24 Previous issues
Filter
Filter
Article type
Keywords
Authors
Funded articles
Volume 36(1); February 2021
Prev issue Next issue
Namgok Lecture 2020
Obesity and Metabolism
Cellular and Intercellular Homeostasis in Adipose Tissue with Mitochondria-Specific Stress
Min Jeong Choi, Saet-Byel Jung, Joon Young Chang, Minho Shong
Endocrinol Metab. 2021;36(1):1-11.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.956
  • 6,021 View
  • 230 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Paracrine interactions are imperative for the maintenance of adipose tissue intercellular homeostasis, and intracellular organelle dysfunction results in local and systemic alterations in metabolic homeostasis. It is currently accepted that mitochondrial proteotoxic stress activates the mitochondrial unfolded protein response (UPRmt) in vitro and in vivo. The induction of mitochondrial chaperones and proteases during the UPRmt is a key cell-autonomous mechanism of mitochondrial quality control. The UPRmt also affects systemic metabolism through the secretion of cell non-autonomous peptides and cytokines (hereafter, metabokines). Mitochondrial function in adipose tissue plays a pivotal role in whole-body metabolism and human diseases. Despite continuing interest in the role of the UPRmt and quality control pathways of mitochondria in energy metabolism, studies on the roles of the UPRmt and metabokines in white adipose tissue are relatively sparse. Here, we describe the role of the UPRmt in adipose tissue, including adipocytes and resident macrophages, and the interactive roles of cell non-autonomous metabokines, particularly growth differentiation factor 15, in local adipose cellular homeostasis and systemic energy metabolism.

Citations

Citations to this article as recorded by  
  • Imeglimin modulates mitochondria biology and facilitates mitokine secretion in 3T3-L1 adipocytes
    Nobuhiko Takahashi, Atsushi P. Kimura, Takayuki Yoshizaki, Kazumasa Ohmura
    Life Sciences.2024; 349: 122735.     CrossRef
  • Mitochondrial stress-induced GFRAL signaling controls diurnal food intake and anxiety-like behavior
    Carla Igual Gil, Bethany M Coull, Wenke Jonas, Rachel N Lippert, Susanne Klaus, Mario Ost
    Life Science Alliance.2022; 5(11): e202201495.     CrossRef
  • Stress-induced FGF21 and GDF15 in obesity and obesity resistance
    Susanne Keipert, Mario Ost
    Trends in Endocrinology & Metabolism.2021; 32(11): 904.     CrossRef
Close layer
Review Articles
Adrenal gland
The Genotype-Based Morphology of Aldosterone-Producing Adrenocortical Disorders and Their Association with Aging
Xin Gao, Yuto Yamazaki, Yuta Tezuka, Kei Omata, Yoshikiyo Ono, Ryo Morimoto, Yasuhiro Nakamura, Fumitoshi Satoh, Hironobu Sasano
Endocrinol Metab. 2021;36(1):12-21.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.101
  • 5,247 View
  • 200 Download
  • 7 Web of Science
  • 7 Crossref
AbstractAbstract PDFPubReader   ePub   
Primary aldosteronism (PA) is the most common cause of secondary hypertension, and is associated with an increased incidence of cardiovascular events. PA itself is clinically classified into the following two types: unilateral PA, mostly composed of aldosteroneproducing adenoma (APA); and bilateral hyperaldosteronism, consisting of multiple aldosterone-producing micronodules (APMs) and aldosterone-producing diffuse hyperplasia. Histopathologically, those disorders above are all composed of compact and clear cells. The cellular morphology in the above-mentioned aldosterone-producing disorders has been recently reported to be closely correlated with patterns of somatic mutations of ion channels including KCNJ5, CACNA1D, ATP1A1, ATP2B3, and others. In addition, in non-pathological adrenal glands, APMs are frequently detected regardless of the status of the renin-angiotensin-aldosterone system (RAAS). Aldosterone-producing nodules have been also proposed as non-neoplastic nodules that can be identified by hematoxylin and eosin staining. These non-neoplastic CYP11B2-positive nodules could represent possible precursors of APAs possibly due to the presence of somatic mutations. On the other hand, aging itself also plays a pivotal role in the development of aldosterone-producing lesions. For instance, the number of APMs was also reported to increase with aging. Therefore, recent studies indicated the novel classification of PA into normotensive PA (RAAS-independent APM) and clinically overt PA.

Citations

Citations to this article as recorded by  
  • Subtype-specific Body Composition and Metabolic Risk in Patients With Primary Aldosteronism
    Seung Shin Park, Chang Ho Ahn, Sang Wan Kim, Ji Won Yoon, Jung Hee Kim
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e788.     CrossRef
  • Temporal trends in clinical features of patients with primary aldosteronism over 20 years
    Seung Shin Park, Chang Ho Ahn, Sang Wan Kim, Jung-Min Koh, Seung Hun Lee, Jung Hee Kim
    Hypertension Research.2024;[Epub]     CrossRef
  • 2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism
    Jeonghoon Ha, Jung Hwan Park, Kyoung Jin Kim, Jung Hee Kim, Kyong Yeun Jung, Jeongmin Lee, Jong Han Choi, Seung Hun Lee, Namki Hong, Jung Soo Lim, Byung Kwan Park, Jung-Han Kim, Kyeong Cheon Jung, Jooyoung Cho, Mi-kyung Kim, Choon Hee Chung
    Endocrinology and Metabolism.2023; 38(6): 597.     CrossRef
  • Correlation of Histopathologic Subtypes of Primary Aldosteronism with Clinical Phenotypes and Postsurgical Outcomes
    Chang Ho Ahn, You-Bin Lee, Jae Hyeon Kim, Young Lyun Oh, Jung Hee Kim, Kyeong Cheon Jung
    The Journal of Clinical Endocrinology & Metabolism.2023;[Epub]     CrossRef
  • Expression of CYP11B1 and CYP11B2 in adrenal adenoma correlates with clinical characteristics of primary aldosteronism
    Chang Ho Ahn, Hee Young Na, So Yeon Park, Hyeong Won Yu, Su‐Jin Kim, June Young Choi, Kyu Eun Lee, Sang Wan Kim, Kyeong Cheon Jung, Jung Hee Kim
    Clinical Endocrinology.2022; 96(1): 30.     CrossRef
  • Pathology of Aldosterone Biosynthesis and its Action
    Xin Gao, Yuto Yamazaki, Yuta Tezuka, Kei Omata, Yoshikiyo Ono, Ryo Morimoto, Yasuhiro Nakamura, Takashi Suzuki, Fumitoshi Satoh, Hironobu Sasano
    The Tohoku Journal of Experimental Medicine.2021; 254(1): 1.     CrossRef
  • Cellular Senescence in Adrenocortical Biology and Its Disorders
    Xin Gao, Faping Li, Bin Liu, Yuxiong Wang, Yishu Wang, Honglan Zhou
    Cells.2021; 10(12): 3474.     CrossRef
Close layer
Diabetes
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Hun Jee Choe, Young Min Cho
Endocrinol Metab. 2021;36(1):22-29.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.102
  • 28,757 View
  • 670 Download
  • 14 Web of Science
  • 15 Crossref
AbstractAbstract PDFPubReader   ePub   
Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering medications with salient benefits for body weight and cardiovascular events. This class of medications is now recommended as the top priority for patients with established cardiovascular disease or indicators of high risk. Until the advent of oral semaglutide, however, GLP-1 receptor agonists were available only in the form of subcutaneous injections. Aversion to needles, discomfort with self-injection, or skin problems at the injection site are commonly voiced problems in people with diabetes, and thus, attempts for non-invasive delivery strategies have continued. Herein, we review the evolution of GLP-1 therapy from its discovery and the development of currently approved drugs to the unprecedented endeavor to administer GLP-1 receptor agonists via the oral route. We focus on the pharmacokinetic and pharmacodynamic properties of the recently approved oral GLP-1 receptor agonist, oral semaglutide. Small molecule oral GLP-1 receptor agonists are currently in development, and we introduce how these chemicals have addressed the challenge posed by interactions with the large extracellular ligand binding domain of the GLP-1 receptor. We specifically discuss the structure and pharmacological properties of TT-OAD2, LY3502970, and PF-06882961, and envision an era where more patients could benefit from oral GLP-1 receptor agonist therapy.

Citations

Citations to this article as recorded by  
  • Sulfobetaine modification of poly (D, L-lactide-co-glycolic acid) nanoparticles enhances mucus permeability and improves bioavailability of orally delivered liraglutide
    Zhenyu Zhao, Ruihuan Ding, Yumei Wang, Ranran Yuan, Houqian Zhang, Tianyang Li, Wei Zheng, Entao Chen, Aiping Wang, Yanan Shi
    Journal of Drug Delivery Science and Technology.2024; 93: 105437.     CrossRef
  • Physiology and pharmacology of glucagon-like peptide-1 receptor
    D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, V. I. Petrov, A. V. Strygin, K. N. Koryanova, Yu. V. Gorbunova, Yu. A. Kolosov, O. V. Ivanova, E. V. Pavlova, M. A. Dzhavakhyan, A. V. Zaborovsky, V. B. Saparova, I. E. Makarenko, R. I. Drai, A. N. Chumachenko
    Pharmacy & Pharmacology.2024; 11(4): 347.     CrossRef
  • G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
    Mohan Patil, Ilaria Casari, Leon N. Warne, Marco Falasca
    Biomedicine & Pharmacotherapy.2024; 172: 116245.     CrossRef
  • Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
    Binbin Gong, Zhihong Yao, Chenxu Zhou, Wenxi Wang, Lidan Sun, Jing Han
    European Journal of Medicinal Chemistry.2024; 269: 116342.     CrossRef
  • The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
    Haowen Fang, Bing Niu, Qin Chen
    Current Medicinal Chemistry.2024; 31(20): 2921.     CrossRef
  • Binding sites and design strategies for small molecule GLP-1R agonists
    Haibo Zhang, Tianxiao Wu, Yong Wu, Yuran Peng, Xian Wei, Tao Lu, Yu Jiao
    European Journal of Medicinal Chemistry.2024; 275: 116632.     CrossRef
  • Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
    Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang, Jincheng Wang
    Acta Pharmaceutica Sinica B.2023; 13(6): 2383.     CrossRef
  • Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
    Shurui Hong, J. Xiao, Y. He
    BIO Web of Conferences.2023; 61: 01006.     CrossRef
  • Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
    Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Panagiotis Stachteas, Konstantinos I. Bougioukas, Aleksandra Klisic, Nikolaos Fragakis, Manfredi Rizzo
    Metabolism.2023; 149: 155710.     CrossRef
  • A review of glucoregulatory hormones potentially applicable to the treatment of Alzheimer’s disease: mechanism and brain delivery
    Reeju Amatya, Kyoung Ah Min, Meong Cheol Shin
    Journal of Pharmaceutical Investigation.2022; 52(2): 195.     CrossRef
  • Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
    Harold E. Bays, Angela Fitch, Sandra Christensen, Karli Burridge, Justin Tondt
    Obesity Pillars.2022; 2: 100018.     CrossRef
  • Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24
    Zhaotong Cong, Qingtong Zhou, Yang Li, Li-Nan Chen, Zi-Chen Zhang, Anyi Liang, Qing Liu, Xiaoyan Wu, Antao Dai, Tian Xia, Wei Wu, Yan Zhang, Dehua Yang, Ming-Wei Wang
    Proceedings of the National Academy of Sciences.2022;[Epub]     CrossRef
  • Improved Split TEV GPCR β-arrestin-2 Recruitment Assays via Systematic Analysis of Signal Peptide and β-arrestin Binding Motif Variants
    Yuxin Wu, Isabelle von Hauff, Niels Jensen, Moritz Rossner, Michael Wehr
    Biosensors.2022; 13(1): 48.     CrossRef
  • GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
    Xin Zhao, Minghe Wang, Zhitong Wen, Zhihong Lu, Lijuan Cui, Chao Fu, Huan Xue, Yunfeng Liu, Yi Zhang
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class
    Evie K. Bain, Stephen C. Bain
    Diabetes, Obesity and Metabolism.2021; 23(S3): 30.     CrossRef
Close layer
Thyroid
Best Achievements in Clinical Thyroidology in 2020
Eun Kyung Lee, Young Joo Park
Endocrinol Metab. 2021;36(1):30-35.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.103
  • 4,841 View
  • 250 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
This review highlights the most interesting research in thyroidology conducted in 2020. The publications of interest discussed below dealt with the following topics: thyroid dysfunction, risk of thyroid cancer, molecular diagnostics and new therapeutics for thyroid cancer, and thyroid disease in the coronavirus disease 2019 pandemic era.

Citations

Citations to this article as recorded by  
  • Compensation for iodine deficiency conditions with drugs based on duckweed substrate
    M. Kh. Sadulaev, M. I. Usmanova, T. T. Tataev, A. M. Inderbiev, A. S.-A. Zhamalullayla, A. Salamova
    BIO Web of Conferences.2023; 76: 03002.     CrossRef
  • Use of long non-coding RNAs for the molecular diagnosis of papillary thyroid cancer
    Daham Kim, Juyeon Yu, Jiwon Kim, Yoon-a Hwang, Jin Kyong Kim, Cheol Ryong Ku, Jung Hyun Yoon, Jin Young Kwak, Kee-Hyun Nam, Eun Jig Lee
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Ultrasound-Guided Fine-Needle Aspiration with or without Negative Pressure for Different Types of Thyroid Nodules
    Qi Zhou, Wenjun Wu, Fang Wang, Xiaohua Gong, Xiaojun Chen
    International Journal of General Medicine.2021; Volume 14: 5475.     CrossRef
Close layer
Thyroid
Best Achievements in Translational and Basic Thyroidology in 2020
Sun Wook Cho, Young Joo Park
Endocrinol Metab. 2021;36(1):36-40.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.104
  • 3,493 View
  • 140 Download
AbstractAbstract PDFPubReader   ePub   
This review discusses articles published in 2020 that presented noteworthy achievements in translational and basic thyroidology. Previously unresolved questions about thyroid hormone receptor actions and signaling mechanisms were answered using various novel in vitro and in vivo models. Using high resolution cryo-electron microscopy, the fine functional structure of thyroglobulin was demonstrated, and new insights into the pathogenesis of thyroid disease were achieved, with a focus on research into thyroid-disrupting chemicals and the gut microbiome. Novel therapeutic approaches were tried in the field of advanced thyroid cancer treatments.
Close layer
Diabetes
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020
Eun-Jung Rhee, Mee-Kyung Kim, Won-Young Lee
Endocrinol Metab. 2021;36(1):41-50.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.106
  • 4,645 View
  • 180 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives. The categories of anti-diabetic medications expanded from a few to numerous, enabling clinicians to personalize diabetes care and treatment. Thanks to rapid growth in the field of science and medical engineering, newer treatment options are coming to the market with various advantages and disadvantages to be aware of. Therefore, clinicians should rapidly adopt new trends based on guidelines and data from many clinical trials in the field of diabetes. In the treatment of dyslipidemia, trends and guidelines are changing every year, and novel therapies are being developed. In this review, we would like to summarize the major achievements in clinical medicine in 2020 in the field of diabetes mellitus and dyslipidemia.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
    Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
    Diabetes & Metabolism.2023; 49(4): 101440.     CrossRef
  • Effects of exercise initiation and smoking cessation after new-onset type 2 diabetes mellitus on risk of mortality and cardiovascular outcomes
    Mee Kyoung Kim, Kyungdo Han, Bongsung Kim, Jinyoung Kim, Hyuk-Sang Kwon
    Scientific Reports.2022;[Epub]     CrossRef
  • Combined Effects of Obesity and Dyslipidaemia on the Prevalence of Diabetes Amongst Adults Aged ≥45 Years: Evidence from a Nationally Representative Cross-Sectional Study
    Simin Zhang, Donghan Sun, Xiaoyi Qian, Li Li, Wenwen Wu
    International Journal of Environmental Research and Public Health.2022; 19(13): 8036.     CrossRef
  • Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults
    Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim
    Journal of Lipid and Atherosclerosis.2022; 11(3): 288.     CrossRef
Close layer
Hypothalamus and Pituitary gland
Best Achievements in Pituitary and Adrenal Diseases in 2020
Chang Ho Ahn, Jung Hee Kim
Endocrinol Metab. 2021;36(1):51-56.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.108
  • 4,858 View
  • 167 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFPubReader   ePub   
Significant progress in pituitary and adrenal diseases was made in 2020. This review presents major translational and clinical advances in research on pituitary and adrenal diseases, encompassing their epidemiology, pathogenesis, diagnosis, and clinical management. We address the controversy regarding the nomenclature of pituitary neuroendocrine tumors, omics-based molecular classification of pituitary adenomas, and novel drugs for Cushing’s disease in the field of pituitary diseases. In the field of adrenal diseases, we cover big data-driven epidemiology of adrenal tumors, steroid profiling as a new diagnostic tool, and the utility of scoring systems in the decision-making process of managing primary aldosteronism. This brief article will broaden readers’ understanding of pituitary and adrenal diseases.

Citations

Citations to this article as recorded by  
  • Surgical management and outcomes of spinal metastasis of malignant adrenal tumor: A retrospective study of six cases and literature review
    Xiangzhi Ni, Jing Wang, Jiashi Cao, Kun Zhang, Shuming Hou, Xing Huang, Yuanjin Song, Xin Gao, Jianru Xiao, Tielong Liu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • 2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism
    Jeonghoon Ha, Jung Hwan Park, Kyoung Jin Kim, Jung Hee Kim, Kyong Yeun Jung, Jeongmin Lee, Jong Han Choi, Seung Hun Lee, Namki Hong, Jung Soo Lim, Byung Kwan Park, Jung-Han Kim, Kyeong Cheon Jung, Jooyoung Cho, Mi-kyung Kim, Choon Hee Chung
    Endocrinology and Metabolism.2023; 38(6): 597.     CrossRef
Close layer
Editorial
Close layer
Original Articles
Clinical Study
Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
Ki-Hyun Baek, Yoon-Sok Chung, Jung-Min Koh, In Joo Kim, Kyoung Min Kim, Yong-Ki Min, Ki Deok Park, Rajani Dinavahi, Judy Maddox, Wenjing Yang, Sooa Kim, Sang Jin Lee, Hyungjin Cho, Sung-Kil Lim
Endocrinol Metab. 2021;36(1):60-69.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.848
  • 7,291 View
  • 403 Download
  • 7 Web of Science
  • 11 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This phase 3 study evaluated the efficacy and safety of 6-month treatment with romosozumab in Korean postmenopausal women with osteoporosis.
Methods
Sixty-seven postmenopausal women with osteoporosis (bone mineral density [BMD] T-scores ≤–2.5 at the lumbar spine, total hip, or femoral neck) were randomized (1:1) to receive monthly subcutaneous injections of romosozumab (210 mg; n=34) or placebo (n=33) for 6 months.
Results
At month 6, the difference in the least square (LS) mean percent change from baseline in lumbar spine BMD (primary efficacy endpoint) between the romosozumab (9.5%) and placebo (–0.1%) groups was significant (9.6%; 95% confidence interval, 7.6 to 11.5; P<0.001). The difference in the LS mean percent change from baseline was also significant for total hip and femoral neck BMD (secondary efficacy endpoints). After treatment with romosozumab, the percent change from baseline in procollagen type 1 N-terminal propeptide transiently increased at months 1 and 3, while that in C-terminal telopeptide of type 1 collagen showed a sustained decrease. No events of cancer, hypocalcemia, injection site reaction, positively adjudicated atypical femoral fracture or osteonecrosis of the jaw, or positively adjudicated serious cardiovascular adverse events were observed. At month 9, 17.6% and 2.9% of patients in the romosozumab group developed binding and neutralizing antibodies, respectively.
Conclusion
Treatment with romosozumab for 6 months was well tolerated and significantly increased lumbar spine, total hip, and femoral neck BMD compared with placebo in Korean postmenopausal women with osteoporosis (ClinicalTrials.gov identifier NCT02791516).

Citations

Citations to this article as recorded by  
  • Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials
    Takaomi Kobayashi, Megumi Hara, Chisato Shimanoe, Tadatsugu Morimoto, Mawatari Masaaki, Koji Ito, Takafumi Shimazaki
    Journal of Bone and Mineral Metabolism.2024;[Epub]     CrossRef
  • A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
    Zepeng Chen, Ming Li, Shuzhen Li, Yuxi Li, Junyan Wu, Kaifeng Qiu, Xiaoxia Yu, Lin Huang, Guanghui Chen
    Expert Opinion on Drug Safety.2023; 22(4): 339.     CrossRef
  • Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials (CDM‐J)
    Wenbo Huang, Masashi Nagao, Naohiro Yonemoto, Sen Guo, Takeshi Tanigawa, Yuji Nishizaki
    Pharmacoepidemiology and Drug Safety.2023; 32(6): 671.     CrossRef
  • Efficacy and Cardiovascular Safety of Romosozumab: A Meta-analysis and Systematic Review
    Seo-Yong Choi, Jeong-Min Kim, Sang-Hyeon Oh, Seunghyun Cheon, Jee-Eun Chung
    Korean Journal of Clinical Pharmacy.2023; 33(2): 128.     CrossRef
  • Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part I)
    E. Carlos Rodriguez-Merchan, Alonso Moreno-Garcia, Hortensia De la Corte-Rodriguez
    SurgiColl.2023;[Epub]     CrossRef
  • Romosozumab in osteoporosis: yesterday, today and tomorrow
    Dong Wu, Lei Li, Zhun Wen, Guangbin Wang
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review
    Frideriki Poutoglidou, Efthimios Samoladas, Nikolaos Raikos, Dimitrios Kouvelas
    Journal of Clinical Densitometry.2022; 25(3): 401.     CrossRef
  • Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates
    Yun Sun Lee, So Jeong Park, Jin Young Lee, Eunah Choi, Beom-Jun Kim
    The Korean Journal of Internal Medicine.2022; 37(4): 821.     CrossRef
  • What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?
    I. R. Reid
    Expert Opinion on Drug Safety.2022; 21(12): 1441.     CrossRef
  • Proxied Therapeutic Inhibition on Wnt Signaling Antagonists and Risk of Cardiovascular Diseases: Multi-Omics Analyses
    Yu Qian, Cheng-Da Yuan, Saber Khederzadeh, Ming-Yu Han, Hai-Xia Liu, Mo-Chang Qiu, Jian-Hua Gao, Wei-Lin Wang, Yun-Piao Hou, Guo-Bo Chen, Ke-Qi Liu, Lin Xu, David Karasik, Shu-Yang Xie, Hou-Feng Zheng
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Multi-Omics Analyses Identify Pleiotropy and Causality Between Circulating Sclerostin and Atrial Fibrillation
    Yu Qian, Peng-Lin Guan, Saber Khederzadeh, Ke-Qi Liu, Cheng-Da Yuan, Ming-Yu Han, Hai-Xia Liu, Mo-Chang Qiu, Jian-Hua Gao, Wei-Lin Wang, Yun-Piao Hou, Guo-Bo Chen, Lin Xu, David Karasik, Shu-Yang Xie, sheng zhifeng, Hou-Feng Zheng
    SSRN Electronic Journal .2022;[Epub]     CrossRef
Close layer
Clinical Study
Big Data Articles (National Health Insurance Service Database)
Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea
Da Hea Seo, Kyoung Hwa Ha, So Hun Kim, Dae Jung Kim
Endocrinol Metab. 2021;36(1):70-80.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.777
  • 5,484 View
  • 201 Download
  • 5 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Results regarding the cardiovascular (CV) effects of dipeptidyl peptidase-4 (DPP-4) inhibitors are inconsistent. This study aimed to assess the effects of teneligliptin, a DPP-4 inhibitor, on the risk of major CV outcomes in type 2 diabetes mellitus (T2DM) patients compared to sulfonylurea.
Methods
From January 1, 2015 to December 31, 2017, we conducted a retrospective cohort study using the Korean National Health Insurance Service database. A total of 6,682 T2DM patients who were newly prescribed DPP-4 inhibitors or sulfonylurea were selected and matched in a 1:1 ratio by propensity score. The hazard ratios (HRs) for all-cause mortality, hospitalization for heart failure (HHF), all-cause mortality or HHF, myocardial infarction (MI), stroke, and hypoglycemia were assessed.
Results
During 641 days of follow-up, the use of teneligliptin was not associated with an increased risk of all-cause mortality (HR, 1.00; 95% confidence interval [CI], 0.85 to 1.19), HHF (HR, 0.99; 95% CI, 0.86 to 1.14), all-cause mortality or HHF (HR, 1.02; 95% CI, 0.90 to 1.14), MI (HR, 0.90; 95% CI, 0.68 to 1.20), and stroke (HR, 1.00; 95% CI, 0.86 to 1.17) compared to the use of sulfonylurea. However, it was associated with a significantly lower risk of hypoglycemia (HR, 0.68; 95% CI, 0.49 to 0.94) compared to sulfonylurea therapy.
Conclusion
Among T2DM patients, teneligliptin therapy was not associated with an increased risk of CV events including HHF, but was associated with a lower risk of hypoglycemia compared to sulfonylurea therapy.

Citations

Citations to this article as recorded by  
  • Association between age at diagnosis of type 2 diabetes and cardiovascular morbidity and mortality risks: A nationwide population-based study
    Da Hea Seo, Mina Kim, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongbin Hong, So Hun Kim
    Diabetes Research and Clinical Practice.2024; 208: 111098.     CrossRef
  • Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
    R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
    Journal of Endocrinological Investigation.2023; 46(5): 855.     CrossRef
  • Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study
    Harmanjit Singh, Ekta Arora, Seerat Narula, Mandeep Singla, Armaan Otaal, Jatin Sharma
    Expert Review of Endocrinology & Metabolism.2023; 18(4): 347.     CrossRef
  • Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
    Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022.     CrossRef
Close layer
Clinical Study
Efficacy of Ethanol Ablation for Benign Thyroid Cysts and Predominantly Cystic Nodules: A Systematic Review and Meta-Analysis
Cheng-Chun Yang, Yung Hsu, Jyun-Yan Liou
Endocrinol Metab. 2021;36(1):81-95.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.833
  • 6,358 View
  • 239 Download
  • 11 Web of Science
  • 15 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Ultrasound-guided minimally invasive procedures are widely used to treat thyroid diseases. The objective of this study was to assess the efficacy and safety of ethanol ablation (EA) in comparison with other non-surgical options in the treatment of benign thyroid cystic nodules.
Methods
We conducted a systematic search of studies on EA for thyroid cystic nodules, mainly in the Ovid-MEDLINE and Embase, Web of Science, and Cochrane databases. The standardized mean difference (SMD) of the volume reduction ratio (VRR) after EA versus other non-surgical treatments comprised the primary outcome, whereas the odds ratio (OR) of therapeutic success rates between the two groups comprised the secondary outcome.
Results
The meta-analysis included 19 studies (four randomized controlled trials and 15 non-randomized studies) with 1,514 participants. The cumulative VRR of EA was 83.908% (95% confidence interval [CI], 79.358% to 88.457%). EA had a significantly higher pooled VRR (SMD, 0.381; 95% CI, 0.028 to 0.734; P=0.030), but not a significantly higher pooled therapeutic success rate (OR, 0.867; 95% CI, 0.132 to 5.689; P=0.880), than other forms of non-surgical management including radiofrequency ablation (RFA), polidocanol sclerotherapy, and simple aspiration with or without saline flush. However, the VRR and therapeutic success rate were not significantly different between EA and RFA. Major complications were recorded only in six patients (0.53%) with self-limiting dysphonia.
Conclusion
The role of EA as the first-line treatment for benign thyroid cysts and predominantly cystic nodules is supported by its high effectiveness and good safety profile compared to other currently available non-surgical options.

Citations

Citations to this article as recorded by  
  • Ultrasound-guided ethanol ablation versus the Sistrunk operation as a primary treatment for thyroglossal duct cysts
    Dongbin Ahn, Ji Hye Kwak, Gil Joon Lee, Jin Ho Sohn
    Ultrasonography.2024; 43(1): 25.     CrossRef
  • The Comparison of Efficacy and Safety between Radiofrequency Ablation Alone and Ethanol Ablation Followed by Radiofrequency Ablation in the Treatment of Mixed Cystic and Solid Thyroid Nodule
    Min Gang Jo, Min Kyoung Lee, Jae Ho Shin, Min Guk Seo, So Lyung Jung
    Journal of the Korean Society of Radiology.2024; 85(3): 618.     CrossRef
  • Ultrasound-Guided Ethanol Ablation for Thyroglossal Duct Cyst: A Review of Technical Issues and Potential as a New Standard Treatment
    Dongbin Ahn
    Journal of Clinical Medicine.2023; 12(17): 5445.     CrossRef
  • Ultrasound‐Guided Ethanol Ablation as a Primary Treatment for Thyroglossal Duct Cyst: Feasibility, Characteristics, and Outcomes
    Dongbin Ahn, Ji Hye Kwak, Gil Joon Lee, Jin Ho Sohn
    Otolaryngology–Head and Neck Surgery.2023; 168(6): 1381.     CrossRef
  • Ultraschallgeführte lokalablative Verfahren zur Behandlung von Schilddrüsenläsionen
    Johannes-Paul Richter, Carl-Philip Richter, Daniel Gröner
    Angewandte Nuklearmedizin.2023; 46(02): 169.     CrossRef
  • A Case of Thyroid Abscess Following Ethanol Ablation for Benign Thyroid Nodule
    Heungrae Cho, Dongbin Ahn, Ji Hye Kwak, Gil Joon Lee
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2023; 66(9): 624.     CrossRef
  • Sclerotherapy with a Viscum Album Extract for the Two Patients with Cystic Thyroid Nodule
    Jae Ha Lee, Seung Won Lee, Ki Nam Park
    International Journal of Thyroidology.2023; 16(1): 139.     CrossRef
  • Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies: A systematic review, meta-analysis and economic evaluation
    Beatriz León-Salas, Aránzazu Hernández-Yumar, Diego Infante-Ventura, Aythami de Armas Castellano, Yadira González Hernández, Renata Linertová, Teresa Téllez Santana, Pedro de Pablos-Velasco, María M. Trujillo-Martín
    Endocrinología, Diabetes y Nutrición.2023; 70(9): 572.     CrossRef
  • Ultraschallgeführte lokalablative Verfahren zur Behandlung von Schilddrüsenläsionen
    Johannes-Paul Richter, Carl-Philip Richter, Daniel Gröner
    Laryngo-Rhino-Otologie.2023; 102(12): 916.     CrossRef
  • Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies: A systematic review, meta-analysis and economic evaluation
    Beatriz León-Salas, Aránzazu Hernández-Yumar, Diego Infante-Ventura, Aythami de Armas Castellano, Yadira González Hernández, Renata Linertová, Teresa Téllez Santana, Pedro de Pablos-Velasco, María M. Trujillo-Martín
    Endocrinología, Diabetes y Nutrición (English ed.).2023; 70(9): 572.     CrossRef
  • Safety and Efficacy of Ultrasound-Guided Radiofrequency Ablation for Benign Nonfunctional Thyroid Nodules in Children: A Retrospective Study of 62 Patients with Over Four Years of Follow-Up
    Liwen Li, Xinguang Qiu
    Thyroid.2022; 32(5): 525.     CrossRef
  • Ethanol ablation for the treatment of benign thyroid nodules
    Gabrielle K. Steinl, Latoya A. Stewart, Catherine McManus, James A. Lee, Jennifer H. Kuo
    The American Journal of Surgery.2022; 224(1): 408.     CrossRef
  • Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group
    Giovanni Mauri, Stella Bernardi, Andrea Palermo, Roberto Cesareo, Enrico Papini, Luigi Solbiati, Daniele Barbaro, Salvatore Monti, Maurilio Deandrea, Laura Fugazzola, Giovanni Gambelunghe, Roberto Negro, Stefano Spiezia, Fulvio Stacul, Luca Maria Sconfien
    Endocrine.2022; 76(1): 1.     CrossRef
  • Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors
    Arian Mansur, Tushar Garg, Apurva Shrigiriwar, Vahid Etezadi, Christos Georgiades, Peiman Habibollahi, Timothy C. Huber, Juan C. Camacho, Sherif G. Nour, Alan Alper Sag, John David Prologo, Nariman Nezami
    Diagnostics.2022; 12(6): 1300.     CrossRef
  • Approach to FNA of Thyroid Gland Cysts
    Esther Diana Rossi, Pietro Tralongo, Vincenzo Fiorentino, Mariangela Curatolo, Carmine Bruno, Carmen De Crea, Marco Raffaelli, Alfredo Pontecorvi, Luigi Maria Larocca
    Advances in Anatomic Pathology.2022; 29(6): 358.     CrossRef
Close layer
Clinical Study
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinol Metab. 2021;36(1):96-105.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.819
  • 6,360 View
  • 192 Download
  • 16 Web of Science
  • 15 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Several cancers show increased levels of lactate dehydrogenase A (LDHA), which are associated with cancer progression. However, it remains unclear whether LDHA levels are associated with papillary thyroid cancer (PTC) aggressiveness or with the presence of the PTC prognostic marker, the BRAFV600E mutation. This study aimed to evaluate the potential of LDHA as a PTC prognostic marker.
Methods
LDHA expression was examined in 83 PTC tissue specimens by immunohistochemistry. Human thyroid cell lines were genetically manipulated to overexpress BRAFV600E or were treated with a BRAF-specific short hairpin RNA (shBRAF), whose effects on LDHA expression were evaluated by Western blotting. Data from 465 PTC patients were obtained from The Cancer Genome Atlas (TCGA) database and analyzed to validate the in vitro results.
Results
LDHA was aberrantly overexpressed in PTC. Intense immunostaining for LDHA was observed in PTC specimens carrying mutated BRAF, whereas the intensity was less in wild-type BRAF samples. Overexpression of BRAFV600E resulted in LDHA upregulation, whereas treatment with shBRAF downregulated LDHA in human thyroid cell lines. Furthermore, LDHA mRNA expression was significantly elevated and associated with BRAFV600E expression in thyroid cancer tissues from TCGA database. Additionally, LDHA overexpression was found to be correlated with aggressive clinical features of PTC, such as lymph node metastases and advanced tumor stages.
Conclusion
LDHA overexpression is associated with the BRAFV600E mutation and an aggressive PTC behavior. Therefore, LDHA may serve as a biomarker and therapeutic target in PTC.

Citations

Citations to this article as recorded by  
  • Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks
    Ning Qu, Di Chen, Ben Ma, Lijun Zhang, Qiuping Wang, Yuting Wang, Hongping Wang, Zhaoxian Ni, Wen Wang, Tian Liao, Jun Xiang, Yulong Wang, Shi Jin, Dixin Xue, Weili Wu, Yu Wang, Qinghai Ji, Hui He, Hai-long Piao, Rongliang Shi
    Nature Communications.2024;[Epub]     CrossRef
  • Fibroblast growth factor pathway promotes glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner in prostate cancer
    Yongkang Ye, Fukan Yang, Zhanhao Gu, Wenxuan Li, Yinjiao Yuan, Shaoqian Liu, Le Zhou, Bo Han, Ruinian Zheng, Zhengguo Cao
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Lactate Dehydrogenase A is Associated with Elevated FDG Metabolism, Radioiodine Non-avidity, and Poor Prognosis in Differentiated Thyroid Cancer
    Tian Tian, Hongyuan Dai, Mengni Zhang, Minggang Su, Xueqin Chen, Rui Huang
    Academic Radiology.2024;[Epub]     CrossRef
  • Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
    Cassie Pan, Qian Vicky Wu, Jenna Voutsinas, Jeffrey J. Houlton, Brittany Barber, Zain H. Rizvi, Emily Marchiano, Neal Futran, George E. Laramore, Jay J. Liao, Upendra Parvathaneni, Renato G. Martins, Jonathan R. Fromm, Cristina P. Rodriguez
    Cancer Medicine.2023; 12(8): 9384.     CrossRef
  • LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and radioiodine resistance in papillary thyroid cancer
    Liang Shi, Rui Duan, Zhenhua Sun, Qiong Jia, Wenyu Wu, Feng Wang, Jianjun Liu, Hao Zhang, Xue Xue
    Cell Death & Differentiation.2023; 30(6): 1517.     CrossRef
  • Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer
    Guochao Ye, Xiaomei Zhang, Mansheng Li, Zixiang Lin, Yongcan Xu, Haoru Dong, Jie Zhou, Jiaqi Zhang, Sheng Wang, Yunping Zhu, Xiaobo Yu, Xu Qian
    BMC Cancer.2023;[Epub]     CrossRef
  • Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype
    Marianna Aprile, Simona Cataldi, Caterina Perfetto, Antonio Federico, Alfredo Ciccodicola, Valerio Costa
    British Journal of Cancer.2023; 129(2): 249.     CrossRef
  • circNFATC3 facilitated the progression of oral squamous cell carcinoma via the miR-520h/LDHA axis
    Hongguo Xie, Xiaopeng Lu
    Open Medicine.2023;[Epub]     CrossRef
  • The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer
    Sai-li Duan, Min Wu, Zhe-Jia Zhang, Shi Chang
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • CENPE and LDHA were potential prognostic biomarkers of chromophobe renal cell carcinoma
    Hui-feng Wu, Hao Liu, Zhe-wei Zhang, Ji-min Chen
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Classification for Staging and Managing Patients with Biopolymer-induced Human Adjuvant Disease
    Jaime Eduardo Pachón Suárez, Marcela C. Salazar, Victor Z. Rizo
    Plastic and Reconstructive Surgery - Global Open.2022; 10(2): e4137.     CrossRef
  • Development of Metabolic Synthetic Lethality and Its Implications for Thyroid Cancer
    Sang-Hyeon Ju, Seong Eun Lee, Yea Eun Kang, Minho Shong
    Endocrinology and Metabolism.2022; 37(1): 53.     CrossRef
  • Drug delivery for metabolism targeted cancer immunotherapy
    Taravat Khodaei, Sahil Inamdar, Abhirami P. Suresh, Abhinav P. Acharya
    Advanced Drug Delivery Reviews.2022; 184: 114242.     CrossRef
  • Sulfur quantum dot based fluorescence assay for lactate dehydrogenase activity detection
    Shengnan Fan, Xiaoqing Li, Fanghui Ma, Minghui Yang, Juan Su, Xiang Chen
    Journal of Photochemistry and Photobiology A: Chemistry.2022; 430: 113989.     CrossRef
  • STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis
    Nan Huo, Rui Cong, Zhi-jia Sun, Wen-chao Li, Xiang Zhu, Chun-yuan Xue, Zhao Chen, Lu-yuan Ma, Zhong Chu, Yu-chen Han, Xiao-feng Kang, Song-hao Jia, Nan Du, Lei Kang, Xiao-jie Xu
    Cell Death & Disease.2021;[Epub]     CrossRef
Close layer
Clinical Study
Association of Vitamin D Deficiency with Diabetic Nephropathy
So-hyeon Hong, Young Bin Kim, Hoon Sung Choi, Tae-Dong Jeong, Jin Taek Kim, Yeon Ah Sung
Endocrinol Metab. 2021;36(1):106-113.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.826
  • 8,934 View
  • 234 Download
  • 25 Web of Science
  • 25 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Low 25-hydroxyvitamin D (25OHD) levels are associated with the incidence of type 2 diabetes mellitus (T2DM). However, the association between 25OHD and metabolic health status or diabetic complications is inconclusive. We evaluated this relationship between vitamin D status and metabolic parameters and complications of T2DM.
Methods
This study included 1,392 patients with T2DM who visited Eulji and Ewha Diabetes Center between January 2011 and August 2016. Anthropometric parameters and laboratory tests including glycated hemoglobin (HbA1c), lipid profile, liver and kidney function, and urinary albumin-to-creatinine ratio (UACR) were evaluated. Diabetic macro- and microvascular complications were determined through a medical record review. Serum 25OHD concentrations were measured by chemiluminescent immunoassay.
Results
The mean 25OHD level was 16.8±9.6 ng/mL. Vitamin D deficiency (<20 ng/mL) and severe deficiency (<10 ng/mL) were observed in 990 (71.1%) and 351 (25.2%) participants, respectively. 25OHD level was positively correlated with age and highdensity lipoprotein cholesterol (HDL-C) level and negatively correlated with HbA1c, triglyceride level, and UACR. HDL-C and UACR were significantly associated with 25OHD after adjusting for other variables. Vitamin D deficiency was independently related to nephropathy after adjusting for confounding variables.
Conclusion
Vitamin D deficiency was common among Korean T2DM patients; it was independently associated with microalbuminuria and HDL level, and positively related to diabetic nephropathy.

Citations

Citations to this article as recorded by  
  • ED-71 ameliorates bone regeneration in type 2 diabetes by reducing ferroptosis in osteoblasts via the HIF1α pathway
    Maoshan Wang, Yingxue Liu, Houda Gui, Gaoqiang Ma, Binyang Li, Zhanwei Zhang, Gyeonghwi Yu, Ailin Wu, Xin Xu, Dongjiao Zhang
    European Journal of Pharmacology.2024; 969: 176303.     CrossRef
  • Vitamin D metabolism in diabetic nephropathy
    Z. V. Abilov, R. Kh. Salimkhanov, A. A. Povaliaeva, A. Yu. Zhukov, E. A. Pigarova, L. K. Dzeranova, L. Ya. Rozhinskaya
    Obesity and metabolism.2024; 20(4): 283.     CrossRef
  • Telmisartan ameliorates nephropathy and restores the hippo pathway in rats with metabolic syndrome
    Badria Mohamed, Salah A. Ghareib, Amira Ebrahim Alsemeh, Shaimaa S. El-Sayed
    European Journal of Pharmacology.2024; 973: 176605.     CrossRef
  • The impact of vitamin D on the etiopathogenesis and the progression of type 1 and type 2 diabetes in children and adults
    Candong Li, Jiaowen Fu, Yipeng Ye, Junsen Li, Yangli He, Tuanyu Fang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • 25(OH)D level and vascular lesion scores in kidney histopathology as risk-stratification tool for predicting renal progression in people with type 2 diabetes
    Suyan Duan, Fang Lu, Rui Sun, Chen Chen, Si Chen, Luhan Geng, Li Qian, Ying Pan, Chengning Zhang, Ming Zeng, Bin Sun, Huijuan Mao, Bo Zhang, Changying Xing, Yanggang Yuan
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(5): 103037.     CrossRef
  • COVID-19 infection and metabolic comorbidities: Mitigating role of nutritional sufficiency and drug – nutraceutical combinations of vitamin D
    Sumit Kumar Mandal, Meghana Tare, P.R. Deepa
    Human Nutrition & Metabolism.2023; 31: 200179.     CrossRef
  • Effects of Vitamin D Supplementation in Diabetic Kidney Disease: A Systematic Review
    Thais de Oliveira e Silva Ullmann, Beatrys Juliani Ramalho, Lucas Fornari Laurindo, Ricardo José Tofano, Claudio José Rubira, Elen Landgraf Guiguer, Sandra Maria Barbalho, Uri Adrian Prync Flato, Katia Portero Sloan, Adriano Cressoni Araujo
    Journal of Renal Nutrition.2023; 33(5): 618.     CrossRef
  • Diabetic Nephropathy: Significance of Determining Oxidative Stress and Opportunities for Antioxidant Therapies
    Marina Darenskaya, Sergey Kolesnikov, Natalya Semenova, Lyubov Kolesnikova
    International Journal of Molecular Sciences.2023; 24(15): 12378.     CrossRef
  • Association between serum 25- hydroxyvitamin D and albuminuiria in middle-aged and older Chinese patients with type 2 diabetes
    Luyan Zhang, Qian Guo, Yanjia Xu, Wenzhen Wei, Yu Wang
    BMC Endocrine Disorders.2023;[Epub]     CrossRef
  • Vitamin D deficiency and its associated factors among patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Mitku Mammo Taderegew, Gashaw Garedew Woldeamanuel, Alemayehu Wondie, Atsede Getawey, Abera Nesiru Abegaz, Fentahun Adane
    BMJ Open.2023; 13(10): e075607.     CrossRef
  • Progression of diabetic nephropathy and vitamin D serum levels: A pooled analysis of 7722 patients
    Yomna E. Dean, Sameh Samir Elawady, Wangpan Shi, Ahmed A. Salem, Arinnan Chotwatanapong, Haya Ashraf, Tharun Reddi, Prashant Obed Reddy Dundi, Waleed Yasser Habash, Mohamed Yasser Habash, Safaa Ahmed, Hana M. Samir, Ahmed Elsayed, Aryan Arora, Abhinav Aro
    Endocrinology, Diabetes & Metabolism.2023;[Epub]     CrossRef
  • Incidence of Vitamin D Deficiency and Its Association With Microalbuminuria in Patients With Type 2 Diabetes Mellitus
    Muhammad Hamza Riaz, Ammar Jamil, Hira Yousaf, Muhammad Hassan, Muhammad Ahmer Sohaib, Sharjeel Babar, Muhammad Hassan Ahmad, Ibtesam Allahi, Muhammad Zeshan Mehmood, Tayyab Mumtaz Khan
    Cureus.2023;[Epub]     CrossRef
  • The Role of Vitamin D in Diabetic Nephropathy: A Translational Approach
    Charlotte Delrue, Reinhart Speeckaert, Joris R. Delanghe, Marijn M. Speeckaert
    International Journal of Molecular Sciences.2022; 23(2): 807.     CrossRef
  • Associations of serum amyloid A and 25‐hydroxyvitamin D with diabetic nephropathy: A cross‐sectional study
    Qian Liu, Jin Sun, Tongdao Xu, Guangrong Bian, Fumeng Yang
    Journal of Clinical Laboratory Analysis.2022;[Epub]     CrossRef
  • Formulation Strategies for Improving the Stability and Bioavailability of Vitamin D-Fortified Beverages: A Review
    Elsa F. Vieira, Suene Souza
    Foods.2022; 11(6): 847.     CrossRef
  • Association between Vitamin D Status and Mortality among Adults with Diabetic Kidney Disease
    Feng Xu, Hongyu Lu, Tianwen Lai, Ling Lin, Yongsong Chen, Pratibha V. Nerurkar
    Journal of Diabetes Research.2022; 2022: 1.     CrossRef
  • Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus
    Seyed Alireza Zomorodian, Maryam Shafiee, Zeinab Karimi, Fatemeh Masjedi, Amirhossein Roshanshad
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • Association of Serum 25 (OH) Vitamin D With Chronic Kidney Disease Progression in Type 2 Diabetes
    Suyan Duan, Fang Lu, Buyun Wu, Chengning Zhang, Guangyan Nie, Lianqin Sun, Zhimin Huang, Honglei Guo, Bo Zhang, Changying Xing, Yanggang Yuan
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • The Influence of Dietary Supplementations on Neuropathic Pain
    Francesco D’Egidio, Giorgia Lombardozzi, Housem E. Kacem Ben Haj M’Barek, Giada Mastroiacovo, Margherita Alfonsetti, Annamaria Cimini
    Life.2022; 12(8): 1125.     CrossRef
  • Emergence of Ectopic Adrenal Tissues-What are the Probable Mechanisms?
    Gürkan Tarçın, Oya Ercan
    Journal of Clinical Research in Pediatric Endocrinology.2022; 14(3): 258.     CrossRef
  • Nutritional Supplements for the Treatment of Neuropathic Pain
    Khaled M. Abdelrahman, Kevin V. Hackshaw
    Biomedicines.2021; 9(6): 674.     CrossRef
  • Vitamin D Deficiency as a Predictor of a High Prevalence of Coronary Artery Disease in Pancreas Transplant Candidates With Type 1 Diabetes
    Małgorzata Buksińska-Lisik, Przemysław J. Kwasiborski, Robert Ryczek, Wojciech Lisik, Artur Mamcarz
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Serum 25-hydroxyvitamin D and Metabolic Parameters in Healthy Korean Adults: Korean National Health and Nutrition Examination Survey VI
    Jeonghoon Ha, Hansang Baek, Chaiho Jeong, Hyunsam Kim, Ki-Hyun Baek, Moo Il Kang, Dong-Jun Lim
    International Journal of General Medicine.2021; Volume 14: 5233.     CrossRef
  • Association Between 25(OH)Vitamin D, HbA1c and Albuminuria in Diabetes Mellitus: Data From a Population-Based Study (VIDAMAZON)
    João Soares Felício, Hana Andrade de Rider Britto, Pedro Celeira Cortez, Fabrício de Souza Resende, Manuela Nascimento de Lemos, Lorena Vilhena de Moraes, Vitória Teixeira de Aquino, Fernanda de Souza Parente, Natércia Neves Marques de Queiroz, João Felíc
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Vitamin D Analogs Can Retard the Onset or Progression of Diabetic Kidney Disease: A Systematic Review
    Samuel N. Uwaezuoke
    Frontiers in Clinical Diabetes and Healthcare.2021;[Epub]     CrossRef
Close layer
Clinical Study
Longitudinal Changes of High Molecular Weight Adiponectin are Associated with Postpartum Development of Type 2 Diabetes Mellitus in Patients with Gestational Diabetes Mellitus
Dong-Hwa Lee, Jung Ah Lim, Jung Hee Kim, Soo Heon Kwak, Sung Hee Choi, Hak Chul Jang
Endocrinol Metab. 2021;36(1):114-122.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.831
  • 4,352 View
  • 108 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
The influence of serial changes of adipokines on maternal glucose metabolism from pregnancy to postpartum periods in women with previous gestational diabetes mellitus (pGDM) has not been thoroughly explored. We tried to examine the relationship between the serial changes of adipokines and the development of diabetes mellitus (DM) in women with pGDM.
Methods
We longitudinally measured following adipokines: high molecular weight (HMW) adiponectin, retinol-binding protein-4 (RBP-4), lipocalin-2, and chemerin, during pregnancy, and at 2 months and 3 years after delivery. Based on glucose status at postpartum 3 years, we divided into three groups: normal glucose tolerance (GDM-NGT, n=20), impaired glucose tolerance (GDM-IGT, n=23), and GDM-DM (n=22). We analyzed the correlations between adipokines and various metabolic parameters.
Results
Plasma HMW adiponectin levels were not different among the three groups during pregnancy. However, HMW adiponectin levels increased at 3 years after the delivery in women with GDM-NGT compared with women with GDM-DM. In the GDM-IGT group, HMW adiponectin levels increased at 2 months postpartum compared to pregnancy period. In contrast, HMW adiponectin levels showed no alternation after parturition in women with GDM-DM. HMW adiponectin was negatively correlated with body mass index and a homeostasis model assessment of insulin resistance. Other adipokines such as RBP-4, lipocalin-2, and chemerin neither showed any differences among the groups nor any significant correlations with 3 years postpartum status of glucose intolerance.
Conclusion
Serial changes of HMW adiponectin are associated with the maintenance of glucose metabolism in women with pGDM after delivery.

Citations

Citations to this article as recorded by  
  • Reproductive risk factors across the female lifecourse and later metabolic health
    Amy R. Nichols, Jorge E. Chavarro, Emily Oken
    Cell Metabolism.2024; 36(2): 240.     CrossRef
  • Gestational Diabetes Mellitus and Colostral Appetite-Regulating Adipokines
    Jolanta Lis-Kuberka, Marta Berghausen-Mazur, Magdalena Orczyk-Pawiłowicz
    International Journal of Molecular Sciences.2024; 25(7): 3853.     CrossRef
  • The levels of osteopontin in human milk of Chinese mothers and its associations with maternal body composition
    Huijuan Ruan, Qingya Tang, Xuan Zhao, Yajie Zhang, Xuelin Zhao, Yi Xiang, Wei Geng, Yi Feng, Wei Cai
    Food Science and Human Wellness.2022; 11(5): 1419.     CrossRef
  • Association of circulatory adiponectin with the parameters of Madras Diabetes Research Foundation-Indian Diabetes Risk Score
    MohdD Khan, MohammadK Ahmad, Roshan Alam, Saba Khan, Geeta Jaiswal, MohammadM Khan
    Journal of Diabetology.2022; 13(4): 331.     CrossRef
Close layer
Clinical Study
Molecular Correlates and Nuclear Features of Encapsulated Follicular-Patterned Thyroid Neoplasms
Chan Kwon Jung, Andrey Bychkov, Dong Eun Song, Jang-Hee Kim, Yun Zhu, Zhiyan Liu, Somboon Keelawat, Chiung-Ru Lai, Mitsuyoshi Hirokawa, Kaori Kameyama, Kennichi Kakudo
Endocrinol Metab. 2021;36(1):123-133.   Published online February 24, 2021
DOI: https://doi.org/10.3803/EnM.2020.860
  • 5,677 View
  • 160 Download
  • 11 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Assessing nuclear features is diagnostically challenging in the aspect of thyroid pathology. The aim of this study was to determine whether pathologists could distinguish BRAF-like and RAS-like nuclear features morphologically and identify morphological features to differentiate thyroid tumors with RAS-like mutations from encapsulated papillary thyroid carcinoma (PTC) with predominant follicular growth and BRAFV600E mutation.
Methods
Representative whole slide images of 16 encapsulated thyroid tumors with predominant follicular growth were reviewed by 12 thyroid pathologists using a web browser-based image viewer. Total nuclear score was calculated from semi-quantitatively scored eight nuclear features. The molecular profile of RAS and BRAF genes was determined by Sanger sequencing.
Results
Total nuclear score ranging 0 to 24 could differentiate BRAF-like tumors from RAS-like tumors with a cut-off value of score 14. The interobserver agreement was the highest for the assessment of nuclear pseudoinclusions (NPIs) but the lowest for nuclear elongation and sickle-shaped nuclei. NPIs were found in tumors with BRAFV600E mutation, but not in tumors with RAS-like mutations. Total nuclear scores were significantly higher for tumors with BRAFV600E than for those with RAS-like mutations (P<0.001).
Conclusion
Our results suggest that NPIs and high nuclear scores have diagnostic utility as rule-in markers for differentiating PTC with BRAFV600E mutation from benign or borderline follicular tumors with RAS-like mutations. Relaxation of rigid criteria for nuclear features resulted in an overdiagnosis of PTC. Immunostaining or molecular testing for BRAFV600E mutation is a useful adjunct for cases with high nuclear scores to identify true PTC.

Citations

Citations to this article as recorded by  
  • Differentiating BRAF V600E- and RAS-like alterations in encapsulated follicular patterned tumors through histologic features: a validation study
    Chankyung Kim, Shipra Agarwal, Andrey Bychkov, Jen-Fan Hang, Agnes Stephanie Harahap, Mitsuyoshi Hirokawa, Kennichi Kakudo, Somboon Keelawat, Chih-Yi Liu, Zhiyan Liu, Truong Phan-Xuan Nguyen, Chanchal Rana, Huy Gia Vuong, Yun Zhu, Chan Kwon Jung
    Virchows Archiv.2024; 484(4): 645.     CrossRef
  • Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases
    Kun-Ping Shih, Yu-Cheng Lee, Jia-Jiun Tsai, Shu-Hui Lin, Chih-Yi Liu, Wan-Shan Li, Chien-Feng Li, Jen-Fan Hang
    Endocrine Pathology.2024;[Epub]     CrossRef
  • The Presence of Typical “BRAFV600E-Like” Atypia in Papillary Thyroid Carcinoma is Highly Specific for the Presence of the BRAFV600E Mutation
    John Turchini, Loretta Sioson, Adele Clarkson, Amy Sheen, Leigh Delbridge, Anthony Glover, Mark Sywak, Stan Sidhu, Anthony J. Gill
    Endocrine Pathology.2023; 34(1): 112.     CrossRef
  • Could Oxidative Stress Play a Role in the Development and Clinical Management of Differentiated Thyroid Cancer?
    Maria Kościuszko, Angelika Buczyńska, Adam Jacek Krętowski, Anna Popławska-Kita
    Cancers.2023; 15(12): 3182.     CrossRef
  • Pitfalls in thyroid pathology and the medicolegal aspects of error
    David N Poller
    Diagnostic Histopathology.2023; 29(11): 495.     CrossRef
  • Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression
    Agnes Stephanie Harahap, Imam Subekti, Sonar Soni Panigoro, Asmarinah, Lisnawati, Retno Asti Werdhani, Hasrayati Agustina, Dina Khoirunnisa, Mutiah Mutmainnah, Fajar Lamhot Gultom, Abdillah Hasbi Assadyk, Maria Francisca Ham
    Biomedicines.2023; 11(10): 2803.     CrossRef
  • The Asian Thyroid Working Group, from 2017 to 2023
    Kennichi Kakudo, Chan Kwon Jung, Zhiyan Liu, Mitsuyoshi Hirokawa, Andrey Bychkov, Huy Gia Vuong, Somboon Keelawat, Radhika Srinivasan, Jen-Fan Hang, Chiung-Ru Lai
    Journal of Pathology and Translational Medicine.2023; 57(6): 289.     CrossRef
  • Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Tumour Entity with a Short History. A Review on Challenges in Our Microscopes, Molecular and Ultrasonographic Profile
    Ivana Kholová, Elina Haaga, Jaroslav Ludvik, David Kalfert, Marie Ludvikova
    Diagnostics.2022; 12(2): 250.     CrossRef
  • Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach
    Chan Kwon Jung, Andrey Bychkov, Kennichi Kakudo
    Endocrinology and Metabolism.2022; 37(5): 703.     CrossRef
  • Different Threshold of Malignancy for RAS-like Thyroid Tumors Causes Significant Differences in Thyroid Nodule Practice
    Kennichi Kakudo
    Cancers.2022; 14(3): 812.     CrossRef
  • The Incidence of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Meta-Analysis Assessing Worldwide Impact of the Reclassification
    Chanchal Rana, Huy Gia Vuong, Thu Quynh Nguyen, Hoang Cong Nguyen, Chan Kwon Jung, Kennichi Kakudo, Andrey Bychkov
    Thyroid.2021;[Epub]     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism